IM Cannabis Corp. has announced a significant leadership change with the appointment of Ronen Zalayet as the new Chief Executive Officer. Zalayet succeeds Oren Shuster, who has resigned from both his CEO position and as a director of the company. This transition is part of IM Cannabis's strategy to expand its technology-driven business operations.

The announcement was made on November 20, 2026, and highlights the company's commitment to enhancing its focus on technology within the medicinal cannabis sector. The change comes at a time when the industry is increasingly looking towards innovative solutions to meet the growing demands of patients and consumers.

Background

IM Cannabis Corp. operates in the medicinal chemicals and botanical products sector, specifically focusing on medical cannabis. The company is listed on the Nasdaq under the ticker IMCC and is classified under the SIC code 2833. Recent filings indicate that the company is in a phase of evaluating and building technology-driven businesses beyond its core operations in medical cannabis.

What the Filing Says

The recent filing states, "On November 20, 2026, IM Cannabis Corp. issued a press release... announcing that Ronen Zalayet was appointed Chief Executive Officer of the Company, succeeding Oren Shuster, who resigned from that role." Additionally, Ohad Melnik has been appointed as an independent director of the company.

Impact

This leadership change may affect various stakeholders, including employees, investors, and patients relying on the company's medical cannabis products. Zalayet's extensive experience in financial leadership positions is expected to bring a fresh perspective to the company's strategic direction.

What's Next

The filing does not say what happens next.